Work

Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.1010

Authors: Anton Mikhailovich Safonov, Chaitanya Bandlamudi, Pier Selenica, Antonio Marra, Emanuela Ferraro, Diana Mandelker, David B. Solit, Michael F. Berger, Larry Norton, Simon N. Powell, Ronglai Shen, Mark E. Robson, Sarat Chandarlapaty, Jorge S. Reis-Filho, Pedram Razavi

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Conquer Cancer Foundation

OpenAlex ID: W4281674851

Cites:

Cited by: 11

Related to: 10